Squarepoint Ops LLC decreased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 58.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,490 shares of the company's stock after selling 60,696 shares during the period. Squarepoint Ops LLC owned approximately 0.07% of Ginkgo Bioworks worth $417,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in Ginkgo Bioworks in the fourth quarter valued at $29,000. KBC Group NV acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at $31,000. KLP Kapitalforvaltning AS acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at $46,000. Mercer Global Advisors Inc. ADV acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at $116,000. Finally, Palumbo Wealth Management LLC acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at $144,000. Institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Price Performance
DNA stock traded up $0.34 during trading hours on Friday, reaching $7.57. The stock had a trading volume of 1,511,134 shares, compared to its average volume of 1,449,336. The stock has a market capitalization of $443.09 million, a PE ratio of -0.58 and a beta of 1.25. The stock has a 50-day simple moving average of $7.31 and a 200 day simple moving average of $9.02. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $22.60.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). The firm had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. On average, sell-side analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
About Ginkgo Bioworks
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
